BMY vs. GEHC: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at BMY and GEHC, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | BMY | GEHC |
|---|---|---|
| Company Name | Bristol-Myers Squibb Company | GE HealthCare Technologies Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Pharmaceuticals | Health Care Equipment & Supplies |
| Market Capitalization | 96.21 billion USD | 33.47 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | June 1, 1972 | December 15, 2022 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of BMY and GEHC by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | BMY | GEHC |
|---|---|---|
| 5-Day Price Return | 3.66% | -1.10% |
| 13-Week Price Return | 2.90% | 0.66% |
| 26-Week Price Return | -0.76% | 6.77% |
| 52-Week Price Return | -13.62% | -16.81% |
| Month-to-Date Return | 2.58% | -1.96% |
| Year-to-Date Return | -16.44% | -6.01% |
| 10-Day Avg. Volume | 17.73M | 4.34M |
| 3-Month Avg. Volume | 14.17M | 3.53M |
| 3-Month Volatility | 25.37% | 27.17% |
| Beta | 0.31 | 1.29 |
Profitability
Return on Equity (TTM)
BMY
34.66%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.85%
- Q1
- 5.40%
- Min
- -10.91%
In the upper quartile for the Pharmaceuticals industry, BMY’s Return on Equity of 34.66% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
GEHC
23.75%
Health Care Equipment & Supplies Industry
- Max
- 29.93%
- Q3
- 16.99%
- Median
- 9.28%
- Q1
- 5.10%
- Min
- -12.52%
In the upper quartile for the Health Care Equipment & Supplies industry, GEHC’s Return on Equity of 23.75% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Net Profit Margin (TTM)
BMY
12.57%
Pharmaceuticals Industry
- Max
- 40.67%
- Q3
- 19.07%
- Median
- 12.31%
- Q1
- 4.50%
- Min
- -9.91%
BMY’s Net Profit Margin of 12.57% is aligned with the median group of its peers in the Pharmaceuticals industry. This indicates its ability to convert revenue into profit is typical for the sector.
GEHC
10.95%
Health Care Equipment & Supplies Industry
- Max
- 24.41%
- Q3
- 13.71%
- Median
- 10.08%
- Q1
- 5.96%
- Min
- -5.58%
GEHC’s Net Profit Margin of 10.95% is aligned with the median group of its peers in the Health Care Equipment & Supplies industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin (TTM)
BMY
20.01%
Pharmaceuticals Industry
- Max
- 45.78%
- Q3
- 23.14%
- Median
- 16.68%
- Q1
- 7.98%
- Min
- -7.13%
BMY’s Operating Profit Margin of 20.01% is around the midpoint for the Pharmaceuticals industry, indicating that its efficiency in managing core business operations is typical for the sector.
GEHC
13.52%
Health Care Equipment & Supplies Industry
- Max
- 31.09%
- Q3
- 18.11%
- Median
- 15.07%
- Q1
- 8.48%
- Min
- -0.28%
GEHC’s Operating Profit Margin of 13.52% is around the midpoint for the Health Care Equipment & Supplies industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | BMY | GEHC |
|---|---|---|
| Return on Equity (TTM) | 34.66% | 23.75% |
| Return on Assets (TTM) | 6.42% | 6.41% |
| Net Profit Margin (TTM) | 12.57% | 10.95% |
| Operating Profit Margin (TTM) | 20.01% | 13.52% |
| Gross Profit Margin (TTM) | 73.15% | 40.80% |
Financial Strength
Current Ratio (MRQ)
BMY
1.27
Pharmaceuticals Industry
- Max
- 4.65
- Q3
- 2.64
- Median
- 1.85
- Q1
- 1.26
- Min
- 0.78
BMY’s Current Ratio of 1.27 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.
GEHC
1.18
Health Care Equipment & Supplies Industry
- Max
- 5.19
- Q3
- 3.00
- Median
- 2.13
- Q1
- 1.44
- Min
- 0.86
GEHC’s Current Ratio of 1.18 falls into the lower quartile for the Health Care Equipment & Supplies industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
BMY
2.64
Pharmaceuticals Industry
- Max
- 1.75
- Q3
- 0.82
- Median
- 0.35
- Q1
- 0.13
- Min
- 0.00
With a Debt-to-Equity Ratio of 2.64, BMY operates with exceptionally high leverage compared to the Pharmaceuticals industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
GEHC
1.03
Health Care Equipment & Supplies Industry
- Max
- 1.61
- Q3
- 0.76
- Median
- 0.45
- Q1
- 0.14
- Min
- 0.00
GEHC’s leverage is in the upper quartile of the Health Care Equipment & Supplies industry, with a Debt-to-Equity Ratio of 1.03. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
Interest Coverage Ratio (TTM)
BMY
-4.77
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 43.60
- Median
- 9.83
- Q1
- 2.37
- Min
- -42.71
BMY has a negative Interest Coverage Ratio of -4.77. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
GEHC
6.19
Health Care Equipment & Supplies Industry
- Max
- 56.35
- Q3
- 25.56
- Median
- 9.60
- Q1
- 3.78
- Min
- -26.49
GEHC’s Interest Coverage Ratio of 6.19 is positioned comfortably within the norm for the Health Care Equipment & Supplies industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | BMY | GEHC |
|---|---|---|
| Current Ratio (MRQ) | 1.27 | 1.18 |
| Quick Ratio (MRQ) | 1.17 | 0.93 |
| Debt-to-Equity Ratio (MRQ) | 2.64 | 1.03 |
| Interest Coverage Ratio (TTM) | -4.77 | 6.19 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
BMY
5.24%
Pharmaceuticals Industry
- Max
- 7.14%
- Q3
- 3.45%
- Median
- 2.17%
- Q1
- 0.33%
- Min
- 0.00%
With a Dividend Yield of 5.24%, BMY offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.
GEHC
0.19%
Health Care Equipment & Supplies Industry
- Max
- 4.15%
- Q3
- 1.76%
- Median
- 0.79%
- Q1
- 0.00%
- Min
- 0.00%
GEHC’s Dividend Yield of 0.19% is consistent with its peers in the Health Care Equipment & Supplies industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
BMY
82.80%
Pharmaceuticals Industry
- Max
- 199.58%
- Q3
- 97.17%
- Median
- 53.47%
- Q1
- 22.97%
- Min
- 0.00%
BMY’s Dividend Payout Ratio of 82.80% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
GEHC
2.80%
Health Care Equipment & Supplies Industry
- Max
- 160.00%
- Q3
- 66.60%
- Median
- 27.49%
- Q1
- 0.00%
- Min
- 0.00%
GEHC’s Dividend Payout Ratio of 2.80% is within the typical range for the Health Care Equipment & Supplies industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | BMY | GEHC |
|---|---|---|
| Dividend Yield (TTM) | 5.24% | 0.19% |
| Dividend Payout Ratio (TTM) | 82.80% | 2.80% |
Valuation
Price-to-Earnings Ratio (TTM)
BMY
15.80
Pharmaceuticals Industry
- Max
- 45.19
- Q3
- 27.91
- Median
- 20.59
- Q1
- 15.08
- Min
- 3.79
BMY’s P/E Ratio of 15.80 is within the middle range for the Pharmaceuticals industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
GEHC
15.10
Health Care Equipment & Supplies Industry
- Max
- 67.29
- Q3
- 47.01
- Median
- 30.94
- Q1
- 23.91
- Min
- 10.79
In the lower quartile for the Health Care Equipment & Supplies industry, GEHC’s P/E Ratio of 15.10 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Price-to-Sales Ratio (TTM)
BMY
1.99
Pharmaceuticals Industry
- Max
- 8.87
- Q3
- 4.56
- Median
- 2.14
- Q1
- 1.58
- Min
- 0.11
BMY’s P/S Ratio of 1.99 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
GEHC
1.65
Health Care Equipment & Supplies Industry
- Max
- 9.49
- Q3
- 5.41
- Median
- 2.86
- Q1
- 2.07
- Min
- 0.74
In the lower quartile for the Health Care Equipment & Supplies industry, GEHC’s P/S Ratio of 1.65 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio (MRQ)
BMY
4.95
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.99
- Median
- 2.48
- Q1
- 1.53
- Min
- 0.59
BMY’s P/B Ratio of 4.95 is within the conventional range for the Pharmaceuticals industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
GEHC
3.43
Health Care Equipment & Supplies Industry
- Max
- 10.85
- Q3
- 6.56
- Median
- 3.53
- Q1
- 2.36
- Min
- 0.71
GEHC’s P/B Ratio of 3.43 is within the conventional range for the Health Care Equipment & Supplies industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | BMY | GEHC |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 15.80 | 15.10 |
| Price-to-Sales Ratio (TTM) | 1.99 | 1.65 |
| Price-to-Book Ratio (MRQ) | 4.95 | 3.43 |
| Price-to-Free Cash Flow Ratio (TTM) | 6.24 | 23.91 |